dc.creator | Conde, Esther | es |
dc.creator | Rojo, Federico | es |
dc.creator | Gómez, Javier | es |
dc.creator | Enguita, Ana Belén | es |
dc.creator | Abdulkader, Ihab | es |
dc.creator | González, Ana | es |
dc.creator | Álava | es |
dc.creator | Álava Casado, Enrique de | es |
dc.date.accessioned | 2022-10-24T15:36:22Z | |
dc.date.available | 2022-10-24T15:36:22Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Conde, E., Rojo, F., Gómez, J., Enguita, A.B., Abdulkader, I., González, A.,...,Álava Casado, E.d. (2021). Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing. Journal of clinical pathology, 75 (3), 145-153. https://doi.org/10.1136/jclinpath-2021-207490. | |
dc.identifier.issn | 0021-9746 | es |
dc.identifier.uri | https://hdl.handle.net/11441/138288 | |
dc.description.abstract | The effectiveness of targeted therapies with tyrosine
kinase inhibitors in non-small-cell lung cancer (NSCLC)
depends on the accurate determination of the genomic
status of the tumour. For this reason, molecular analyses
to detect genetic rearrangements in some genes (ie, ALK,
ROS1, RET and NTRK) have become standard in patients
with advanced disease. Since immunohistochemistry is
easier to implement and interpret, it is normally used
as the screening procedure, while fluorescence in situ
hybridisation (FISH) is used to confirm the rearrangement
and decide on ambiguous immunostainings. Although
FISH is considered the most sensitive method for
the detection of ALK and ROS1 rearrangements, the
interpretation of results requires detailed guidelines. In
this review, we discuss the various technologies available
to evaluate ALK and ROS1 genomic rearrangements
using these techniques. Other techniques such as real time PCR and next-generation sequencing have been
developed recently to evaluate ALK and ROS1 gene
rearrangements, but some limitations prevent their full
implementation in the clinical setting. Similarly, liquid
biopsies have the potential to change the treatment of
patients with advanced lung cancer, but further research
is required before this technology can be applied
in routine clinical practice. We discuss the technical
requirements of laboratories in the light of quality
assurance programmes. Finally, we review the recent
updates made to the guidelines for the determination of
molecular biomarkers in patients with NSCLC. | es |
dc.format | application/pdf | es |
dc.format.extent | 9 p. | es |
dc.language.iso | eng | es |
dc.publisher | BMJ Publishing Group | es |
dc.relation.ispartof | Journal of clinical pathology, 75 (3), 145-153. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Molecular diagnosis | es |
dc.subject | ROS1 testing | es |
dc.title | Molecular diagnosis in non-small-cell lung cancer: expert opinion on ALK and ROS1 testing | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Citología e Histología Normal y Patológica | es |
dc.relation.publisherversion | https://jcp.bmj.com/content/75/3/145 | es |
dc.identifier.doi | 10.1136/jclinpath-2021-207490 | es |
dc.contributor.group | Universidad de Sevilla. CTS-1035: Patología Molecular del Cáncer Sólido | es |
dc.journaltitle | Journal of clinical pathology | es |
dc.publication.volumen | 75 | es |
dc.publication.issue | 3 | es |
dc.publication.initialPage | 145 | es |
dc.publication.endPage | 153 | es |